FDA rejects highly-anticipated diet drug Qnexa

Oct 29, 2010 By MATTHEW PERRONE , AP Business Writer

(AP) -- Federal health regulators have decided not to approve an experimental diet pill called Qnexa, which had been touted by many experts as the most promising weight-loss drug in more than a decade.

The drug's maker, Vivus Inc., said in a statement Thursday that the declined to approve the drug in its present form. The agency asked for more study results and additional information on its possible health risks, including major and risks for women of childbearing potential.

The FDA did not ask for any new clinical studies, but more may be required if the agency's concerns aren't addressed, Vivus said.

The company plans to respond to the FDA in about six weeks.

"We remain confident in the efficacy and safety profile of Qnexa demonstrated in the clinical development program and look forward to continue working with the FDA towards the approval for the treatment of obesity," Vivus CEO Leland Wilson said in a statement.

Its shares added 5 cents to $6.18 in aftermarket trading Thursday. The stock added 5 cents to $6.13 during the regular session.

Vivus, based in Mountain View, Calif., is one of three small drugmakers racing to win approval for their weight-loss drugs. Many analysts picked Qnexa as the most promising contender because of the high level of weight loss reported in company studies: On average, patients lost more than 10 percent total . That compared to weight loss of under 5 percent with drugs currently on the market, like Roche's Xenical.

But Qnexa's outlook took a significant hit in July, when a panel of experts assembled by the FDA voted 10-6 to not recommend the drug's approval. Panelists said the drug was associated with a number of dangerous side effects, including , heart palpitations, memory lapses and .

With rates of obesity and diabetes rising globally, doctors say new weight-loss drugs are needed, though the drug class has a history of safety problems.

Vivus is the second weight-loss drug rejected by the FDA in the past week. On Saturday, Arena Pharmaceuticals announced that the agency declined to approve its drug lorcaserin, citing tumors seen in rats during early stage testing. The San Diego-based company said it still hopes to win approval for the drug and would submit more detailed information, at the agency's request.

FDA's rejection of drugs from Vivus and Arena will focus new attention on the third competitor in the weight-loss drug race: Orexigen Therapeutics. The company's drug Contrave has shown weight loss between 5 and 10 percent with modest side effects, though FDA's decisions this week suggest a strict standard for safety.

One of the key researchers in the development of Qnexa warned that the FDA's negative decision on the drug could have a cooling effect on industry efforts.

"If there isn't any kind of path forward for this drug I think it is going to shut down all obesity drug development for a decade," said Dr. Tim Garvey of the University of Alabama. Garvey conducted two clinical trials of Qnexa and has consulted for Vivus.

"Why would a company put all that investment into developing a drug if the FDA signals they aren't willing to approve it," he said.

With U.S. obesity rates nearing 35 percent among adults, doctors and public health officials say new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential.

But the search for a drug that helps patients safely shed pounds has been largely unsuccessful. Two weeks ago Abbott Laboratories withdrew its pill Meridia from U.S. and Canadian markets after regulators said it increased the risk of heart attack and stroke.

Explore further: FDA approves hard-to-abuse narcotic painkiller

4.5 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Vivus weight loss drug faces FDA panel this week

Jul 13, 2010

(AP) -- Vivus Inc.'s experimental drug Qnexa was effective in cutting weight, the Food and Drug Administration said Tuesday, while acknowledging lingering concerns over the drug's nervous system and psychiatric side effects.

FDA panel rejects experimental weight loss pill

Jul 15, 2010

(AP) -- A panel of federal health experts dealt a surprising setback Thursday to a highly anticipated anti-obesity pill from Vivus Inc., saying the drug's side effects outweigh its ability to help patients lose weight.

FDA to review first of 3 new weight loss drugs

Jul 12, 2010

(AP) -- Dieters, doctors and investors get their first extensive look at the first of a trio of new weight loss drugs this week. The hope is that the new drugs can succeed where many others have failed: delivering significant ...

Diet drugs face tough test before FDA

Sep 17, 2010

There has never been a magic prescription to help millions of obese Americans lose weight. Whether one is any closer to reality is now under scrutiny.

Experimental diet pill shows promise, little risk

Jul 14, 2010

(AP) -- An experimental diet pill helped about half the people who tried it lose some weight and keep it off a year later, without the heart problems that some earlier drugs caused, a study found.

Abbott withdraws diet pill in US, Canada

Oct 08, 2010

(AP) -- Abbott Laboratories said Friday it will withdraw its diet pill Meridia in the U.S. and Canada, almost a year after studies showed the drug increases the risk of heart attack and stroke in patients with a history ...

Recommended for you

FDA approves hard-to-abuse narcotic painkiller

12 hours ago

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

13 hours ago

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

13 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

Tough-to-abuse formulation of oxycodone approved

13 hours ago

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe pain when other ...

EU regulator: Morning-after pill OK for all women

Jul 24, 2014

(AP)—A commonly used morning-after pill is suitable for use by heavier women, the European Medicines Agency said Thursday after a review of the evidence sparked by the French manufacturer's declaration that the drugs didn't ...

Physicians warned about counterfeit medical devices

Jul 24, 2014

(HealthDay)—Physicians should be aware of the prevalence and serious consequences associated with use of counterfeit medical devices, according to a letter to the editor published online July 20 in Lasers in ...

User comments : 0